Computer-Aided Drug Discovery Market By Type (Structure Based Drug Design, Ligand-Based Drug Design, Sequence-Based Approaches), By Therapeutic Area (Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, Diabetes, Others), By End User (Pharmaceutical Companies, Biotechnology Companies, Research Laboratories): Global Opportunity Analysis and Industry Forecast, 2021-2030
The global computer-aided drug discovery market was valued at $2,940.9 million in 2021 and is projected to reach $7,504.7 million by 2030, growing at a CAGR of 11.48% from 2022 to 2030.
The prevalence of chronic diseases, such as cardiovascular disease, has risen dramatically in recent years. According to the World Health Organization (WHO), the United Nations (UN) specialized agency responsible for international public health, the number of CVD patients may reach 23 million by the end of 2030. Furthermore, according to Premier, Inc., a notable healthcare improvement company, the demand for novel drugs for the treatment of CVD conditions has skyrocketed as a result of the COVID-19 crisis. The facts and figures presented above show that the need for the development of new drug molecules is expected to rise, which may have a positive impact on the global computer-aided drug discovery market during the analysis period.
However, lack of skilled labor for operating computer aided drug discovery solutions may hamper the global market growth. Also, lower product penetration in the emerging economies is also restraining the global computer-aided drug discovery market.
Emerging concepts such as artificial intelligence (AI) and big data in computer-aided drug discovery, on the other hand, may drive the market over the forecast period. Many aspects of drug discovery can benefit from artificial intelligence, including drug design, chemical synthesis, drug screening, drug repurposing, and polypharmacology.
The global computer-aided drug discovery market is segmented on the basis of type, therapeutic area, end-user, and region. By type, the market is classified into structure-based drug design (SBDD), ligand-based drug design (LBDD), and sequence-based approaches. By therapeutic area, the analysis has been divided into oncology, neurology, cardiovascular disease, respiratory disease, diabetes, and others. By end-user, the market has been divided into pharmaceutical companies, biotechnology companies and research laboratories. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in this report include BOCSCI Inc., Bioduro-Sundia, Schrödinger, Inc., Aragen Life Sciences Pvt. Ltd., Aris Pharmaceuticals, Inc, Charles River Laboratories, Bayer AG, AstraZeneca, and Albany Molecular Research Inc. (AMRI).
KEY MARKET SEGMENTS
By Type
Structure-based Drug Design
Ligand-based Drug Design
Sequence-based Approaches
By Therapeutic Area
Oncology
Neurology
Cardiovascular Disease
Respiratory Disease
Diabetes
Others
By End user
Pharmaceutical Companies
Biotechnology Companies
Research Laboratories
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
BOCSCI Inc.,
Bioduro-Sundia,
Schrödinger, Inc.,
Aragen Life Sciences Pvt. Ltd.,
Aris Pharmaceuticals, Inc,
Charles River Laboratories,
Bayer AG,
AstraZeneca,
Albany Molecular Research Inc. (AMRI).
Key Market Segments
By Type
Structure Based Drug Design
Ligand-Based Drug Design
Sequence-Based Approaches
By Therapeutic Area
Oncology
Neurology
Cardiovascular Disease
Respiratory Disease
Diabetes
Others
By End User
Pharmaceutical Companies
Biotechnology Companies
Research Laboratories
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest Of Asia Pacific
LAMEA
Brazil
Saudi Arabia
UAE
South Africa
Rest of LAMEA
Key Market Players
charles river laboratories
BOC Sciences
Bioduro-Sundia
Schrödinger, Inc.
Aragen Life Sciences Pvt. Ltd.
Aris Pharmaceuticals, Inc.
Bayer AG
AstraZeneca plc
Albany Molecular Research Inc. (AMRI)
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.Regulatory Guidelines
- 3.8.Value Chain Analysis
- 3.9.Market Share Analysis
- 3.10.Key Regulation Analysis
- 3.11.Patent Landscape
- CHAPTER 4: COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Structure Based Drug Design
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Ligand-Based Drug Design
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Sequence-Based Approaches
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- CHAPTER 5: COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Oncology
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Neurology
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Cardiovascular Disease
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Respiratory Disease
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.6 Diabetes
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
- 5.7 Others
- 5.7.1 Key market trends, growth factors and opportunities
- 5.7.2 Market size and forecast, by region
- 5.7.3 Market analysis by country
- CHAPTER 6: COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Pharmaceutical Companies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Biotechnology Companies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Research Laboratories
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: COMPUTER-AIDED DRUG DISCOVERY MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Therapeutic Area
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Type
- 7.2.5.1.2 Market size and forecast, by Therapeutic Area
- 7.2.5.1.3 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Type
- 7.2.5.2.2 Market size and forecast, by Therapeutic Area
- 7.2.5.2.3 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Type
- 7.2.5.3.2 Market size and forecast, by Therapeutic Area
- 7.2.5.3.3 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Therapeutic Area
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Type
- 7.3.5.1.2 Market size and forecast, by Therapeutic Area
- 7.3.5.1.3 Market size and forecast, by End User
- 7.3.5.2 United Kingdom
- 7.3.5.2.1 Market size and forecast, by Type
- 7.3.5.2.2 Market size and forecast, by Therapeutic Area
- 7.3.5.2.3 Market size and forecast, by End User
- 7.3.5.3 France
- 7.3.5.3.1 Market size and forecast, by Type
- 7.3.5.3.2 Market size and forecast, by Therapeutic Area
- 7.3.5.3.3 Market size and forecast, by End User
- 7.3.5.4 Spain
- 7.3.5.4.1 Market size and forecast, by Type
- 7.3.5.4.2 Market size and forecast, by Therapeutic Area
- 7.3.5.4.3 Market size and forecast, by End User
- 7.3.5.5 Italy
- 7.3.5.5.1 Market size and forecast, by Type
- 7.3.5.5.2 Market size and forecast, by Therapeutic Area
- 7.3.5.5.3 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Type
- 7.3.5.6.2 Market size and forecast, by Therapeutic Area
- 7.3.5.6.3 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Therapeutic Area
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Type
- 7.4.5.1.2 Market size and forecast, by Therapeutic Area
- 7.4.5.1.3 Market size and forecast, by End User
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Type
- 7.4.5.2.2 Market size and forecast, by Therapeutic Area
- 7.4.5.2.3 Market size and forecast, by End User
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Type
- 7.4.5.3.2 Market size and forecast, by Therapeutic Area
- 7.4.5.3.3 Market size and forecast, by End User
- 7.4.5.4 South Korea
- 7.4.5.4.1 Market size and forecast, by Type
- 7.4.5.4.2 Market size and forecast, by Therapeutic Area
- 7.4.5.4.3 Market size and forecast, by End User
- 7.4.5.5 Australia
- 7.4.5.5.1 Market size and forecast, by Type
- 7.4.5.5.2 Market size and forecast, by Therapeutic Area
- 7.4.5.5.3 Market size and forecast, by End User
- 7.4.5.6 Rest Of Asia Pacific
- 7.4.5.6.1 Market size and forecast, by Type
- 7.4.5.6.2 Market size and forecast, by Therapeutic Area
- 7.4.5.6.3 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Therapeutic Area
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Type
- 7.5.5.1.2 Market size and forecast, by Therapeutic Area
- 7.5.5.1.3 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Type
- 7.5.5.2.2 Market size and forecast, by Therapeutic Area
- 7.5.5.2.3 Market size and forecast, by End User
- 7.5.5.3 UAE
- 7.5.5.3.1 Market size and forecast, by Type
- 7.5.5.3.2 Market size and forecast, by Therapeutic Area
- 7.5.5.3.3 Market size and forecast, by End User
- 7.5.5.4 South Africa
- 7.5.5.4.1 Market size and forecast, by Type
- 7.5.5.4.2 Market size and forecast, by Therapeutic Area
- 7.5.5.4.3 Market size and forecast, by End User
- 7.5.5.5 Rest of LAMEA
- 7.5.5.5.1 Market size and forecast, by Type
- 7.5.5.5.2 Market size and forecast, by Therapeutic Area
- 7.5.5.5.3 Market size and forecast, by End User
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 charles river laboratories
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 BOC Sciences
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Bioduro-Sundia
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Schrödinger, Inc.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Aragen Life Sciences Pvt. Ltd.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Aris Pharmaceuticals, Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Bayer AG
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 AstraZeneca plc
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Albany Molecular Research Inc. (AMRI)
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 2. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR STRUCTURE BASED DRUG DESIGN, BY REGION , 2021-2030,($MILLION)
- TABLE 3. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR STRUCTURE BASED DRUG DESIGN BY COUNTRY, 2021-2030,($MILLION)
- TABLE 4. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR LIGAND-BASED DRUG DESIGN, BY REGION , 2021-2030,($MILLION)
- TABLE 5. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR LIGAND-BASED DRUG DESIGN BY COUNTRY, 2021-2030,($MILLION)
- TABLE 6. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR SEQUENCE-BASED APPROACHES, BY REGION , 2021-2030,($MILLION)
- TABLE 7. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR SEQUENCE-BASED APPROACHES BY COUNTRY, 2021-2030,($MILLION)
- TABLE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 9. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR ONCOLOGY, BY REGION , 2021-2030,($MILLION)
- TABLE 10. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR ONCOLOGY BY COUNTRY, 2021-2030,($MILLION)
- TABLE 11. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR NEUROLOGY, BY REGION , 2021-2030,($MILLION)
- TABLE 12. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR NEUROLOGY BY COUNTRY, 2021-2030,($MILLION)
- TABLE 13. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR CARDIOVASCULAR DISEASE, BY REGION , 2021-2030,($MILLION)
- TABLE 14. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASE BY COUNTRY, 2021-2030,($MILLION)
- TABLE 15. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR RESPIRATORY DISEASE, BY REGION , 2021-2030,($MILLION)
- TABLE 16. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR RESPIRATORY DISEASE BY COUNTRY, 2021-2030,($MILLION)
- TABLE 17. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR DIABETES, BY REGION , 2021-2030,($MILLION)
- TABLE 18. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR DIABETES BY COUNTRY, 2021-2030,($MILLION)
- TABLE 19. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2030,($MILLION)
- TABLE 20. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR OTHERS BY COUNTRY, 2021-2030,($MILLION)
- TABLE 21. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 22. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR PHARMACEUTICAL COMPANIES, BY REGION , 2021-2030,($MILLION)
- TABLE 23. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR PHARMACEUTICAL COMPANIES BY COUNTRY, 2021-2030,($MILLION)
- TABLE 24. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR BIOTECHNOLOGY COMPANIES, BY REGION , 2021-2030,($MILLION)
- TABLE 25. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR BIOTECHNOLOGY COMPANIES BY COUNTRY, 2021-2030,($MILLION)
- TABLE 26. COMPUTER-AIDED DRUG DISCOVERY MARKET REVENUE, FOR RESEARCH LABORATORIES, BY REGION , 2021-2030,($MILLION)
- TABLE 27. COMPUTER-AIDED DRUG DISCOVERY MARKET FOR RESEARCH LABORATORIES BY COUNTRY, 2021-2030,($MILLION)
- TABLE 28. COMPUTER-AIDED DRUG DISCOVERY MARKET, BY REGION, 2021-2030,($MILLION)
- TABLE 29. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 30. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 31. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 32. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2030,($MILLION)
- TABLE 33. U.S. COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 34. U.S. COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 35. U.S. COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 36. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 37. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 38. CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 39. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 40. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 41. MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 42. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 43. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 44. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 45. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2030,($MILLION)
- TABLE 46. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 47. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 48. GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 49. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 50. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 51. UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 52. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 53. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 54. FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 55. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 56. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 57. SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 58. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 59. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 60. ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 61. REST OF EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 62. REST OF EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 63. REST OF EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 64. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 65. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 66. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 67. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2030,($MILLION)
- TABLE 68. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 69. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 70. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 71. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 72. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 73. JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 74. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 75. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 76. INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 77. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 78. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 79. SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 80. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 81. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 82. AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 83. REST OF ASIA PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 84. REST OF ASIA PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 85. REST OF ASIA PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 86. LAMEA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 87. LAMEA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 88. LAMEA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 89. LAMEA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY COUNTRY, 2021-2030,($MILLION)
- TABLE 90. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 91. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 92. BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 93. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 94. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 95. SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 96. UAE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 97. UAE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 98. UAE COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 99. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 100. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 101. SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 102. REST OF LAMEA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE, 2021-2030,($MILLION)
- TABLE 103. REST OF LAMEA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021-2030,($MILLION)
- TABLE 104. REST OF LAMEA COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END USER, 2021-2030,($MILLION)
- TABLE 105.CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
- TABLE 106.CHARLES RIVER LABORATORIES: OPERATING SEGMENTS
- TABLE 107.CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
- TABLE 108.CHARLES RIVER LABORATORIES: NET SALES,
- TABLE 109.CHARLES RIVER LABORATORIES: KEY STRATERGIES
- TABLE 110.BOC SCIENCES: COMPANY SNAPSHOT
- TABLE 111.BOC SCIENCES: OPERATING SEGMENTS
- TABLE 112.BOC SCIENCES: PRODUCT PORTFOLIO
- TABLE 113.BOC SCIENCES: NET SALES,
- TABLE 114.BOC SCIENCES: KEY STRATERGIES
- TABLE 115.BIODURO-SUNDIA: COMPANY SNAPSHOT
- TABLE 116.BIODURO-SUNDIA: OPERATING SEGMENTS
- TABLE 117.BIODURO-SUNDIA: PRODUCT PORTFOLIO
- TABLE 118.BIODURO-SUNDIA: NET SALES,
- TABLE 119.BIODURO-SUNDIA: KEY STRATERGIES
- TABLE 120.SCHRÖDINGER, INC.: COMPANY SNAPSHOT
- TABLE 121.SCHRÖDINGER, INC.: OPERATING SEGMENTS
- TABLE 122.SCHRÖDINGER, INC.: PRODUCT PORTFOLIO
- TABLE 123.SCHRÖDINGER, INC.: NET SALES,
- TABLE 124.SCHRÖDINGER, INC.: KEY STRATERGIES
- TABLE 125.ARAGEN LIFE SCIENCES PVT. LTD.: COMPANY SNAPSHOT
- TABLE 126.ARAGEN LIFE SCIENCES PVT. LTD.: OPERATING SEGMENTS
- TABLE 127.ARAGEN LIFE SCIENCES PVT. LTD.: PRODUCT PORTFOLIO
- TABLE 128.ARAGEN LIFE SCIENCES PVT. LTD.: NET SALES,
- TABLE 129.ARAGEN LIFE SCIENCES PVT. LTD.: KEY STRATERGIES
- TABLE 130.ARIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
- TABLE 131.ARIS PHARMACEUTICALS, INC.: OPERATING SEGMENTS
- TABLE 132.ARIS PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
- TABLE 133.ARIS PHARMACEUTICALS, INC.: NET SALES,
- TABLE 134.ARIS PHARMACEUTICALS, INC.: KEY STRATERGIES
- TABLE 135.BAYER AG: COMPANY SNAPSHOT
- TABLE 136.BAYER AG: OPERATING SEGMENTS
- TABLE 137.BAYER AG: PRODUCT PORTFOLIO
- TABLE 138.BAYER AG: NET SALES,
- TABLE 139.BAYER AG: KEY STRATERGIES
- TABLE 140.ASTRAZENECA PLC: COMPANY SNAPSHOT
- TABLE 141.ASTRAZENECA PLC: OPERATING SEGMENTS
- TABLE 142.ASTRAZENECA PLC: PRODUCT PORTFOLIO
- TABLE 143.ASTRAZENECA PLC: NET SALES,
- TABLE 144.ASTRAZENECA PLC: KEY STRATERGIES
- TABLE 145.ALBANY MOLECULAR RESEARCH INC. (AMRI): COMPANY SNAPSHOT
- TABLE 146.ALBANY MOLECULAR RESEARCH INC. (AMRI): OPERATING SEGMENTS
- TABLE 147.ALBANY MOLECULAR RESEARCH INC. (AMRI): PRODUCT PORTFOLIO
- TABLE 148.ALBANY MOLECULAR RESEARCH INC. (AMRI): NET SALES,
- TABLE 149.ALBANY MOLECULAR RESEARCH INC. (AMRI): KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.COMPUTER-AIDED DRUG DISCOVERY MARKET SEGMENTATION
- FIGURE 2.COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030
- FIGURE 3.COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.COMPUTER-AIDED DRUG DISCOVERY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.REGULATORY GUIDELINES
- FIGURE 13.VALUE CHAIN ANALYSIS
- FIGURE 14.MARKET SHARE ANALYSIS
- FIGURE 15.KEY REGULATION ANALYSIS
- FIGURE 16.PATENT ANALYSIS BY COMPANY
- FIGURE 17.PATENT ANALYSIS BY COUNTRY
- FIGURE 18.COMPUTER-AIDED DRUG DISCOVERY MARKET,BY TYPE,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF STRUCTURE BASED DRUG DESIGN COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF LIGAND-BASED DRUG DESIGN COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF SEQUENCE-BASED APPROACHES COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 22.COMPUTER-AIDED DRUG DISCOVERY MARKET,BY THERAPEUTIC AREA,2021(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ONCOLOGY COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF NEUROLOGY COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CARDIOVASCULAR DISEASE COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 26.COMPARATIVE SHARE ANALYSIS OF RESPIRATORY DISEASE COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 27.COMPARATIVE SHARE ANALYSIS OF DIABETES COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 28.COMPARATIVE SHARE ANALYSIS OF OTHERS COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 29.COMPUTER-AIDED DRUG DISCOVERY MARKET,BY END USER,2021(%)
- FIGURE 30.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL COMPANIES COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 31.COMPARATIVE SHARE ANALYSIS OF BIOTECHNOLOGY COMPANIES COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 32.COMPARATIVE SHARE ANALYSIS OF RESEARCH LABORATORIES COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030(%)
- FIGURE 33.COMPUTER-AIDED DRUG DISCOVERY MARKET BY REGION,2021
- FIGURE 34.U.S. COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 35.CANADA COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 36.MEXICO COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 37.GERMANY COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 38.UNITED KINGDOM COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 39.FRANCE COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 40.SPAIN COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 41.ITALY COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 42.REST OF EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 43.CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 44.JAPAN COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 45.INDIA COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 46.SOUTH KOREA COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 47.AUSTRALIA COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 48.REST OF ASIA PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 49.BRAZIL COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 50.SAUDI ARABIA COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 51.UAE COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 52.SOUTH AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 53.REST OF LAMEA COMPUTER-AIDED DRUG DISCOVERY MARKET,2021-2030($MILLION)
- FIGURE 54. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 55. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 56. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 57.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 58.COMPETITIVE DASHBOARD
- FIGURE 59.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 60.CHARLES RIVER LABORATORIES.: NET SALES ,($MILLION)
- FIGURE 61.BOC SCIENCES.: NET SALES ,($MILLION)
- FIGURE 62.BIODURO-SUNDIA.: NET SALES ,($MILLION)
- FIGURE 63.SCHRÖDINGER, INC..: NET SALES ,($MILLION)
- FIGURE 64.ARAGEN LIFE SCIENCES PVT. LTD..: NET SALES ,($MILLION)
- FIGURE 65.ARIS PHARMACEUTICALS, INC..: NET SALES ,($MILLION)
- FIGURE 66.BAYER AG.: NET SALES ,($MILLION)
- FIGURE 67.ASTRAZENECA PLC.: NET SALES ,($MILLION)
- FIGURE 68.ALBANY MOLECULAR RESEARCH INC. (AMRI).: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook